

CURRICULUM VITAE**Michael LeBlanc, Ph.D.****1. PERSONAL DATA****Place of Birth:** New Westminster, British Columbia, Canada.Contact Information

Public Health Sciences, Biostatistics Program

SWOG Cancer Research Network Statistical

Center 1100 Fairview Avenue, M3-C102

Seattle, WA 98109-1024

Phone: (206) 667-4623

2. EDUCATION

(Biostatistics)

1977-1983 Simon Fraser University, B.Sc. (Mathematics)

1983-1984 University of Waterloo, M.Math. (Statistics)

1985-1989 University of Washington, Ph.D.

1989-1990 Post-doctoral Fellow, University of Washington and Fred Hutchinson Cancer Research Center

3. LICENSURE

N/A

4. PROFESSIONAL POSITIONS HELD

1990-1994 Assistant Professor, Department of Preventive Medicine and Biostatistics, University of Toronto

1991-1994 Associate Member of the School of Graduate Studies, University of Toronto

1992-1994 Assistant Professor, Department of Statistics, University of Toronto (cross appointment)

1995-1996 Assistant Member, Fred Hutchinson Cancer Research Center

1995-1997 Research Assistant Professor, Department of Biostatistics, University of Washington

1996-2001 Associate Member, Fred Hutchinson Cancer Research Center

1997-2002 Research Associate Professor, Department of Biostatistics, University of Washington

2001-Present Professor, Fred Hutchinson Cancer Research Center

2002-Present Research Professor, Department of Biostatistics, University of Washington

2012-Present Group Statistician and Director of Statistical Center, SWOG Cancer Research Network

5. HONORS

1978-1981 Simon Fraser University Open Scholarships

1985-1988 Natural Science and Engineering Research Council Postgraduate Scholarship

1986 Donovan Thompson Award for outstanding achievement in the qualifying examinations of the Biostatistics Program, University of Washington

1986-1988 School of Public Health Tuition Scholarship

1995 Best Paper in the Canadian Journal of Statistics

2019 Fellow of the American Statistical Association

6. PROFESSIONAL ACTIVITIES**A. EDITORIAL RESPONSIBILITIES**

2010-2014 Section Editor (Biostatistics), AACR: Clinical Cancer Research,

2011 Guest Editor, Computational Statistics and Data Analysis, Special issue: Computational Statistics for Clinical Research

2011-Present Associate Editor, Sankhya
 2013-Present Associate Editor, Clinical Trials

B. SPECIAL NATIONAL RESPONSIBILITIES

1. Reviewer

Canadian Society of Epidemiology and
 Biostatistics, Chapman Hall,
 Mathematics Sciences Program—American Mathematical
 Society, Medical Research Council of Canada,
 National Cancer Institute, NIH,
 Natural Sciences and Engineering Research Council of
 Canada, Springer-Verlag

2. National Member

1997-2006 Member, Head and Neck Intergroup Correlative Science Committee, (NCI),
 1998-2004 Member, Independent Data Monitoring Committees for studies in head
 and neck cancer study (TAX322) and gastric cancer study (TAX325),
 (Aventis)
 1998-2005 Consultant, (formerly Mathsoft) Insightful Corporation.
 1999 Consultant, Arkansas Cancer Research Center
 2000-2003 Member, Statistical Committee, American Joint Committee on Cancer
 (American Cancer Society and American College of Surgeons)
 2003-2010 Member, Independent Data Monitoring Committee for studies for MDAnderson
 Cancer Center and Statistics Collaborative, Inc.
 2005-2007 Member, Scientific Program Committee of the American Society of Clinical
 Oncology
 2006-2007 Member, NCI Head and Neck Cancer Steering Committee
 2006-2007 Member, Independent Data Monitoring Committee, J&J Oncology
 2006-present Member, Statistical and Lymphoma Committee, American Joint Committee on
 Cancer (American Cancer Society and American College of Surgeons)
 2007-2010 Member, NCI Head & Neck Steering Committee, Section: Previously Untreated
 Patients
 2007-2010 Member, Independent Data Monitoring Committee, Sanofi-aventis
 2007-2010 Ad Hoc member, Special Emphasis Panel; NCI Epidemiology, Prevention
 Control & Population Sciences P01 Review Committee
 2008-2011 Member, Data Monitoring Committee for the North Central Cancer Treatment
 Group (NCCTG)
 2011-2017 Member, NCI Clinical Trials Design Task Force (Phase II)
 2009-2015 Member, Molecular Modeler Working Group, American Joint Committee on
 Cancer
 2009-2015 Member, Program Assessment of Clinical Cancer Tests (PACCT) NCI working
 group
 2010-2014 Member, Independent Data Monitoring Committee, Lilly Oncology
 2010-Present Member, NCI Imaging Steering Committee
 2011 Ad Hoc member, Special Emphasis Panel: Clinical Assay Development Program,
 NCI
 2012-2017 Member, Advisory Panel for the Group Banking Navigation System
 2015-2019 (CTAC)
 2015-2017 Co-Chair, NCI Clinical Trials Design Task Force (Phase II)
 2015-2016 Member, CTAC Clinical Trials Informatics Working Group (CTIWG)
 2019-2020 Co-Chair, CTAC Strategic Planning Working Group, Statistical Design Subgroup
 2019-2020 Member, CTAC Strategic Planning Working Group, Data Collection Subgroup
 2020-Present Member, Statistical Design Working Group, NCI ComboMATCH study
 2020-Present Co-Chair, Evidence-Based Medicine Team, American Joint Committee on
 Cancer
 2021-Present Member, DSMB, Trial of Rapamycin in Aging Dogs (TRIAD).

C. SPECIAL LOCAL RESPONSIBILITIES**D. University and Fred Hutchinson Cancer Research Center Committees**

1992	MRC self-managed discussion group for young investigators, University of Toronto
1992-1993	Departmental committee for input to the Leyerle Commission, Department of Preventive Medicine and Biostatistics University of Toronto
1992-1994	Member of computer committee, Department of Statistics, University of Toronto
1993	Member of the statistical consulting committee, Department of Statistics
1993	Member of the strategic planning committee, Department of Preventive Medicine and Biostatistics, University of Toronto
1997-2000	Member of the curriculum committee, Department of Biostatistics, University of Washington
1998-2003	Member of statistical theory exam committee, Department of Biostatistics, University of Washington
1998-2006	Member of admissions committee, Department of Biostatistics, University of Washington
2001-2003	Member of faculty Senate, University of Washington
2000-present	Member of faculty search and promotion committees, Fred Hutchinson Cancer Research Center

7. BIBLIOGRAPHY**A. Publications in Refereed Journals**

1. Albain KS, Crowley JJ, **LeBlanc M**, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. *J Clin Oncol*. 1990;8(9):1563-74. doi: 10.1200/JCO.1990.8.9.1563. PubMed PMID: 2167954.
2. Albain KS, Crowley J, **LeBlanc M**, Livingston R. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. *J Clin Oncol*. 1991;9(9):1618-26.
3. Albain KS, Crowley JJ, **LeBlanc M**, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. *J Clin Oncol*. 1991;9(9):1618-26. doi: 10.1200/JCO.1991.9.9.1618. PubMed PMID: 1651993.
4. Albain KS, Green S, **LeBlanc M**, Rivkin S, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. *Breast Cancer Res Treat*. 1992;22(3):273-84. doi: 10.1007/BF01840840. PubMed PMID: 1391993.
5. **LeBlanc M**, Crowley J. Relative risk trees for censored survival data. *Biometrics*. 1992;48(2):411-25. PubMed PMID: 1637970.
6. Tibshirani R, **LeBlanc M**. A Strategy for Binary Description and Classification. *J Comput Graph Stat*. 1992;1(1):3-20. doi: 10.1080/10618600.1992.10474573.
7. Colgan TJ, Pendergast S, **LeBlanc M**. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. *Hum Pathol*. 1993;24(10):1073-7. doi: 10.1016/0046-8177(93)90186-k. PubMed PMID: 8406417.
8. **LeBlanc M**, Crowley J. Survival Trees by Goodness of Split. *J Am Stat Assoc*. 1993;88(422):457-67. doi: 10.2307/2290325. PubMed PMID: WOS:A1993LD68000009.
9. Sagman U, **LeBlanc M**, Maki E, editors. Verification of a multicenter prognostic model for small cell lung cancer (SCLC)[abstract A1125]. *Proc Am Soc Clin Oncol*; 1993.
10. **LeBlanc M**, Tibshirani R. Adaptive Principal Surfaces. *J Am Stat Assoc*. 1994;89(425):53-64. PubMed PMID: WOS:A1994MY54600006.
11. Arnold JE, Rohan T, Howe G, **LeBlanc M**. Reproducibility and validity of a food-frequency questionnaire designed for use in girls age 7 to 12 years. *Ann Epidemiol*. 1995;5(5):369-77. doi: 10.1016/1047-2797(95)00034-5. PubMed PMID: 8653209.
12. **LeBlanc M**. An Adaptive Expansion Method for Regression. *Stat Sinica*. 1995;5(2):737-48. PubMed PMID: WOS:A1995RN08000022.
13. **LeBlanc M**, Crowley J. Step-function covariate effects in the proportional-hazards model. *Canadian Journal of Statistics*. 1995;23(2):109-29.

14. **LeBlanc M**, Crowley J. Semiparametric regression functionals. *J Am Stat Assoc.* 1995;90(429):95-105.
15. Strathdee SA, Frank JW, McLaughlin J, **LeBlanc M**, Major C, O'Shaughnessy MV, et al. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. *J Infect Dis.* 1995;172(5):1375-9. doi: 10.1093/infdis/172.5.1375. PubMed PMID: 7594682.
16. Tammemagi MC, Frank JW, **LeBlanc M**, Artsob H. Intra- and interlaboratory reproducibility of an ELISA serological test for Lyme disease. *Can J Infect Dis.* 1995;6(2):90-5. doi: 10.1155/1995/626945. PubMed PMID: 22416209; PubMed Central PMCID: PMC3298054.
17. Tammemagi MC, Frank JW, **LeBlanc M**, Artsob H, Streiner DL. Methodological issues in assessing reproducibility--a comparative study of various indices of reproducibility applied to repeat ELISA serologic tests for Lyme disease. *J Clin Epidemiol.* 1995;48(9):1123-32. doi: 10.1016/0895-4356(94)00243-j. PubMed PMID: 7636514.
18. **LeBlanc M**, Tibshirani R. Combining estimates in regression and classification. *J Am Stat Assoc.* 1996;91(436):1641-50. doi: Doi 10.2307/2291591. PubMed PMID: WOS:A1996VX91300028.
19. Kasenda M, Calzavara LM, Johnson I, **LeBlanc M**. Correlates of condom use in the young adult population in Ontario. *Can J Public Health.* 1997;88(4):280-5. doi: 10.1007/BF03404798. PubMed PMID: 9336099; PubMed Central PMCID: PMC6990242.
20. **LeBlanc M**. Restricted polynomial regression. *Comput Stat Data An.* 1997;24(2):153-67. doi: Doi 10.1016/S0167-9473(96)00059-X. PubMed PMID: WOS:A1997WR18800002.
21. Al-Sarraf M, **LeBlanc M**, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *J Clin Oncol.* 1998;16(4):1310-7. doi: 10.1200/JCO.1998.16.4.1310. PubMed PMID: 9552031.
22. **LeBlanc M**. Resampled quantile functions for error estimation and a relationship to density estimation. *Comput Stat Data An.* 1998;29(2):163-76. doi: [https://doi.org/10.1016/S0167-9473\(98\)00071-1](https://doi.org/10.1016/S0167-9473(98)00071-1).
23. **LeBlanc M**, Tibshirani R. Monotone shrinkage of trees. *J Comput Graph Stat.* 1998;7(4):417-33. doi: Doi 10.2307/1390674. PubMed PMID: WOS:000077362100001.
24. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. *New England Journal of Medicine.* 1998;339(1):21-6. doi: Doi 10.1056/Nejm199807023390104. PubMed PMID: WOS:000074500000004.
25. Press OW, **LeBlanc M**, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. *J Clin Oncol.* 1998;16(2):574-8. doi: 10.1200/JCO.1998.16.2.574. PubMed PMID: 9469343.
26. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, **LeBlanc M**, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. *J Clin Oncol.* 1998;16(1):48-55. doi: 10.1200/JCO.1998.16.1.48. PubMed PMID: 9440722.
27. **LeBlanc M**, Crowley J. Using the bootstrap for estimation in group sequential designs: an application to a clinical trial for nasopharyngeal cancer. *Stat Med.* 1999;18(19):2635-44. doi: 10.1002/(sici)1097-0258(19991015)18:19<2635::aid-sim200>3.0.co;2-7. PubMed PMID: 10495461.
28. **LeBlanc M**, Crowley J. Adaptive regression splines in the Cox model. *Biometrics.* 1999;55(1):204-13. doi: 10.1111/j.0006-341x.1999.00204.x. PubMed PMID: 11318156.
29. Liu PY, **LeBlanc M**, Desai M. False positive rates of randomized phase II designs. *Control Clin Trials.* 1999;20(4):343-52. doi: 10.1016/s0197-2456(99)00009-4. PubMed PMID: 10440561.
30. Moore DF, Jr., Brown TD, **LeBlanc M**, Dahlberg S, Miller TP, McClure S, et al. Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial. *Invest New Drugs.* 1999;17(2):169-72. doi: 10.1023/a:1006375301205. PubMed PMID: 10638487.
31. Fisher RI, Dana BW, **LeBlanc M**, Kjeldsberg C, Forman JD, Unger JM, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. *J Clin Oncol.* 2000;18(10):2010-6. doi: 10.1200/JCO.2000.18.10.2010. PubMed PMID: 10811664.
32. Taylor CW, **LeBlanc M**, Fisher RI, Moore DF, Sr., Roach RW, Elias L, et al. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. *Anticancer Drugs.* 2000;11(9):695-700. doi: 10.1097/00001813-200010000-00004. PubMed PMID: 11129730.

33. Faraggi D, **LeBlanc M**, Crowley J. Understanding neural networks using regression trees: an application to multiple myeloma survival data. *Stat Med*. 2001;20(19):2965-76. doi: 10.1002/sim.912. PubMed PMID: 11568952.
34. Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA, Jr., Mills GM, **LeBlanc M**, et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. *J Clin Oncol*. 2001;19(3):750-5. doi: 10.1200/JCO.2001.19.3.750. PubMed PMID: 11157027.
35. Kooperberg C, Ruczinski I, **LeBlanc ML**, Hsu L. Sequence analysis using logic regression. *Genet Epidemiol*. 2001;21 Suppl 1:S626-31. doi: 10.1002/gepi.2001.21.s1.s626. PubMed PMID: 11793751.
36. Press OW, **LeBlanc M**, Lichter AS, Grogan TM, Unger JM, Wasserman TH, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. *J Clin Oncol*. 2001;19(22):4238-44. doi: 10.1200/JCO.2001.19.22.4238. PubMed PMID: 11709567.
37. Abdollell M, **LeBlanc M**, Stephens D, Harrison RV. Binary partitioning for continuous longitudinal data: categorizing a prognostic variable. *Stat Med*. 2002;21(22):3395-409. doi: 10.1002/sim.1266. PubMed PMID: 12407680.
38. Kooperberg C, Sipione S, **LeBlanc M**, Strand AD, Cattaneo E, Olson JM. Evaluating test statistics to select interesting genes in microarray experiments. *Hum Mol Genet*. 2002;11(19):2223-32. doi: 10.1093/hmg/11.19.2223. PubMed PMID: 12217950.
39. **LeBlanc M**, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. *Stat Methods Med Res*. 2002;11(3):247-74. doi: 10.1191/0962280202sm286ra. PubMed PMID: 12094758.
40. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, **LeBlanc M**, et al. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. *New England Journal of Medicine*. 2002;346(25):1937-47. doi: 10.1056/nejmoa012914.
41. Blayney DW, **LeBlanc ML**, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). *J Clin Oncol*. 2003;21(13):2466-73. doi: 10.1200/JCO.2003.06.137. PubMed PMID: 12829664.
42. Ditzler S, Stoeck J, **LeBlanc M**, Kooperberg C, Hansen S, Coppin L, et al. A rapid neurobehavioral assessment reveals that FK506 delays symptom onset in R6/2 Huntington's disease mice. *Preclinica*. 2003;1:115-26.
43. **LeBlanc M**, Kooperberg C, Grogan TM, Miller TP. Directed indices for exploring gene expression data. *Bioinformatics*. 2003;19(6):686-93. doi: 10.1093/bioinformatics/btg079. PubMed PMID: WOS:000182328400003.
44. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, **LeBlanc M**, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. *Blood*. 2003;102(5):1606-12. doi: 10.1182/blood-2003-01-0287. PubMed PMID: WOS:000184945200018.
45. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, **LeBlanc M**, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med*. 2003;198(6):851-62. doi: 10.1084/jem.20031074. PubMed PMID: 12975453; PubMed Central PMCID: PMC2194208.
46. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, **LeBlanc M**, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. *Cancer Cell*. 2003;3(2):185-97. doi: 10.1016/s1535-6108(03)00028-x. PubMed PMID: 12620412.
47. Ruczinski I, Kooperberg C, **LeBlanc M**. Logic regression. *J Comput Graph Stat*. 2003;12(3):475-511. doi: 10.1198/1061860032238. PubMed PMID: WOS:000185397600001.
48. Ruczinski I, Kooperberg C, **LeBlanc M**. Logic regression - Methods and software. *Lect Notes Stat*. 2003;171:333-43. PubMed PMID: WOS:000189454900020.
49. Stiff PJ, Unger JM, Forman SJ, McCall AR, **LeBlanc M**, Nademanee AP, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. *Biol Blood Marrow Transplant*. 2003;9(8):529-39. doi: 10.1016/s1083-8791(03)00205-2. PubMed PMID: 12931122.
50. Unger JM, **LeBlanc M**, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, et al. Estimating the

- impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: The Karnofsky memorial lecture. *J Clin Oncol.* 2003;21(23):246s-52s. doi: 10.1200/Jco.2003.08.512. PubMed PMID: WOS:000187043300010.
51. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med.* 2004;351(21):2159-69. doi: 10.1056/NEJMoa041869. PubMed PMID: 15548776.
 52. Nason M, Emerson S, **LeBlanc M**. CARTscans: A tool for visualizing complex models. *J Comput Graph Stat.* 2004;13(4):807-25. doi: 10.1198/106186004x11417. PubMed PMID: WOS:000225739400005.
 53. Rimsza LM, Roberts RA, Miller TP, Unger JM, **LeBlanc M**, Braziel RM, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood.* 2004;103(11):4251-8. doi: 10.1182/blood-2003-07-2365. PubMed PMID: WOS:000221657600046.
 54. Ruczinski I, Kooperberg C, **LeBlanc ML**. Exploring interactions in high-dimensional genomic data: an overview of Logic Regression, with applications. *J Multivariate Anal.* 2004;90(1):178-95. doi: 10.1016/j.jmva.2004.02.010. PubMed PMID: WOS:000221967900009.
 55. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, **LeBlanc M**, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. *Arch Otolaryngol Head Neck Surg.* 2004;130(12):1361-7. doi: 10.1001/archotol.130.12.1361. PubMed PMID: 15611393.
 56. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. *Blood.* 2004;104(5):1258-65. Epub 20040504. doi: 10.1182/blood-2003-12-4434. PubMed PMID: 15126323.
 57. Unger JM, **LeBlanc M**, Thompson IM, Coltman CA, Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. *Urol Oncol.* 2004;22(4):362-8. doi: 10.1016/j.urolonc.2004.04.009. PubMed PMID: 15283898.
 58. Fisher RI, **LeBlanc M**, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. *J Clin Oncol.* 2005;23(33):8447-52. doi: 10.1200/Jco.2005.03.1674. PubMed PMID: WOS:000233411700024.
 59. **LeBlanc M**, Moon J, Crowley J. Adaptive risk group refinement. *Biometrics.* 2005;61(2):370-8. doi: 10.1111/j.1541-0420.2005.020738.x. PubMed PMID: 16011683.
 60. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, **LeBlanc M**, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. *Int J Radiat Oncol.* 2005;61(1):129-36. doi: 10.1016/j.ijrobp.2004.03.040. PubMed PMID: WOS:000226229700020.
 61. Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, **LeBlanc M**, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: A pilot investigation. *Head Neck-J Sci Spec.* 2005;27(6):478-87. doi: 10.1002/hed.20177. PubMed PMID: WOS:000229461600005.
 62. Unger JM, Thompson IM, **LeBlanc M**, Crowley JJ, Goodman PJ, Ford LG, et al. Estimated impact of the prostate cancer prevention trial on population mortality. *Cancer.* 2005;103(7):1375-80. doi: 10.1002/cncr.20919. PubMed PMID: WOS:000227770400008.
 63. Urba SG, Moon J, Giri PGS, Adelstein DJ, Hanna E, Yoo GH, **LeBlanc M**, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: A Southwest Oncology Group trial. *J Clin Oncol.* 2005;23(1):88-95. doi: 10.1200/Jco.2005.04.017. PubMed PMID: WOS:000226380600013.
 64. Adelstein DJ, **LeBlanc M**. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? *J Clin Oncol.* 2006;24(17):2624-8. doi: 10.1200/JCO.2005.05.3629. PubMed PMID: 16763275.
 65. Dai JY, Ruczinski I, **LeBlanc M**, Kooperberg C. Imputation methods to improve inference in SNP association studies. *Genet Epidemiol.* 2006;30(8):690-702. doi: 10.1002/gepi.20180. PubMed PMID: 16986162.
 66. Fan JJ, Su XG, Levine RA, Nunn ME, **LeBlanc M**. Trees for correlated survival data by goodness of split, with applications to tooth prognosis. *J Am Stat Assoc.* 2006;101(475):959-67. doi: 10.1198/016214506000000438. PubMed PMID: WOS:000240158700009.
 67. **LeBlanc M**, Moon J, Kooperberg C. Extreme regression. *Biostatistics.* 2006;7(1):71-84. doi: 10.1093/biostatistics/kxi041. PubMed PMID: WOS:000234220900006.
 68. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, **LeBlanc M**, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. *J Clin*

- Oncol. 2006;24(25):4143-9. Epub 20060808. doi: 10.1200/JCO.2006.05.8198. PubMed PMID: 16896003.
69. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, **LeBlanc M**, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood*. 2006;107(3):1101-7. doi: 10.1182/blood-2005-04-1510. PubMed PMID: WOS:000234991600046.
 70. Agrawal A, Moon J, Davis RK, Sakr WA, Giri SP, Valentino J, **LeBlanc M**, et al. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. *Arch Otolaryngol Head Neck Surg*. 2007;133(10):1044-50. doi: 10.1001/archotol.133.10.1044. PubMed PMID: 17938330.
 71. Roberts RA, Sabalos CM, **LeBlanc ML**, Martel RR, Frutiger YM, Unger JM, et al. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. *Lab Invest*. 2007;87(10):979-97. Epub 20070813. doi: 10.1038/labinvest.3700665. PubMed PMID: 17700562.
 72. Goldman B, **LeBlanc M**, Crowley J. Interim futility analysis with intermediate endpoints. *Clinical Trials*. 2008;5(1):14-22. doi: 10.1177/1740774507086648. PubMed PMID: WOS:000254649200002.
 73. Hoering A, **LeBlanc M**, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. *Clin Cancer Res*. 2008;14(14):4358-67. doi: 10.1158/1078-0432.CCR-08-0288. PubMed PMID: 18628448; PubMed Central PMCID: PMC2569946.
 74. Kooperberg C, **LeBlanc M**. Increasing the power of identifying gene x gene interactions in genome-wide association studies. *Genetic Epidemiology*. 2008;32(3):255-63. doi: 10.1002/gepi.20300. PubMed PMID: WOS:000254690500007.
 75. Persky DO, Unger JM, Spier CM, Stea B, **LeBlanc M**, McCarty MJ, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. *J Clin Oncol*. 2008;26(14):2258-63. Epub 20080414. doi: 10.1200/JCO.2007.13.6929. PubMed PMID: 18413640.
 76. Rimsza LM, **LeBlanc ML**, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. 2008;112(8):3425-33. Epub 20080610. doi: 10.1182/blood-2008-02-137372. PubMed PMID: 18544678; PubMed Central PMCID: PMC4467875.
 77. Swinnen LJ, **LeBlanc M**, Grogan TM, Gordon LI, Stiff PJ, Miller AM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2b, and chemotherapy for posttransplantation lymphoproliferative disorder. *Transplantation*. 2008;86(2):215-22. doi: 10.1097/TP.0b013e3181761659. PubMed PMID: WOS:000257887500008.
 78. Thompson JA, Fisher RI, **LeBlanc M**, Forman SJ, Press OW, Unger JM, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). *Blood*. 2008;111(8):4048-54. doi: 10.1182/blood-2007-09-111708. PubMed PMID: WOS:000255134700026.
 79. Bernstein SH, Unger JM, **LeBlanc M**, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. *J Clin Oncol*. 2009;27(1):114-9. Epub 20081201. doi: 10.1200/JCO.2008.16.8021. PubMed PMID: 19047289; PubMed Central PMCID: PMC4879698.
 80. Dai JY, **LeBlanc M**, Kooperberg C. Semiparametric estimation exploiting covariate independence in two-phase randomized trials. *Biometrics*. 2009;65(1):178-87. Epub 20080513. doi: 10.1111/j.1541-0420.2008.01046.x. PubMed PMID: 18479485; PubMed Central PMCID: PMC2892338.
 81. Dai JY, **LeBlanc M**, Smith NL, Psaty B, Kooperberg C. SHARE: an adaptive algorithm to select the most informative set of SNPs for candidate genetic association. *Biostatistics*. 2009;10(4):680-93. Epub 20090715. doi: 10.1093/biostatistics/kxp023. PubMed PMID: 19605740; PubMed Central PMCID: PMC2742496.
 82. Kooperberg C, **LeBlanc M**, Dai JY, Rajapakse I. Structures and Assumptions: Strategies to Harness Gene x Gene and Gene x Environment Interactions in GWAS. *Stat Sci*. 2009;24(4):472-88. doi: 10.1214/09-sts287. PubMed PMID: 20640184; PubMed Central PMCID: PMC2904990.
 83. **LeBlanc M**, Kooperberg C. Adaptively weighted association statistics. *Genet Epidemiol*. 2009;33(5):442-52. doi: 10.1002/gepi.20397. PubMed PMID: 19170133; PubMed Central PMCID:

- PMC3571103.
84. **LeBlanc M**, Rankin C, Crowley J. Multiple Histology Phase II Trials. *Clin Cancer Res.* 2009;15(13):4256-62. Epub 20090623. doi: 10.1158/1078-0432.CCR-08-2069. PubMed PMID: 19549777.
 85. Rubinstein L, Crowley J, Ivy P, **LeBlanc M**, Sargent D. Randomized phase II designs. *Clin Cancer Res.* 2009;15(6):1883-90. Epub 20090310. doi: 10.1158/1078-0432.CCR-08-2031. PubMed PMID: 19276275; PubMed Central PMCID: PMC3774021.
 86. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, **LeBlanc M**, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. *Leuk Lymphoma.* 2009;50(5):728-35. doi: 10.1080/10428190902856808. PubMed PMID: 19373598; PubMed Central PMCID: PMC3532923.
 87. Yoo GH, Moon J, **LeBlanc M**, Lonardo F, Urba S, Kim H, et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. *Arch Otolaryngol Head Neck Surg.* 2009;135(9):869-74. doi: 10.1001/archoto.2009.122. PubMed PMID: 19770418; PubMed Central PMCID: PMC3098124.
 88. Hatton BA, Villavicencio EH, Pritchard J, **LeBlanc M**, Hansen S, Ulrich M, et al. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. *Oncogene.* 2010;29(26):3865-72. doi: 10.1038/onc.2010.142. PubMed PMID: WOS:000279385200014.
 89. Kooperberg C, **LeBlanc M**, Obenchain V. Risk Prediction Using Genome-Wide Association Studies. *Genetic Epidemiology.* 2010;34(7):643-52. doi: 10.1002/gepi.20509. PubMed PMID: WOS:000283965400001.
 90. **LeBlanc M**, Kooperberg C. Boosting predictions of treatment success. *P Natl Acad Sci USA.* 2010;107(31):13559-60. doi: 10.1073/pnas.1008052107. PubMed PMID: WOS:000280605900001.
 91. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, et al. The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. *Clin Cancer Res.* 2010;16(6):1764-9. doi: 10.1158/1078-0432.Ccr-09-3287. PubMed PMID: WOS:000278595600010.
 92. Sweetenham JW, Goldman B, **LeBlanc ML**, Cook JR, Tubbs RR, Press OW, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. *Ann Oncol.* 2010;21(6):1196-202. doi: 10.1093/annonc/mdp460. PubMed PMID: WOS:000278223700010.
 93. Williamson SK, Moon J, Huang CH, Guaglianone PP, **LeBlanc M**, Wolf GT, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. *J Clin Oncol.* 2010;28(20):3330-5. Epub 20100524. doi: 10.1200/JCO.2009.25.6834. PubMed PMID: 20498388; PubMed Central PMCID: PMC2903329.
 94. Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SHI, **LeBlanc M**, et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. *Invest New Drug.* 2011;29(2):352-9. doi: 10.1007/s10637-009-9348-z. PubMed PMID: WOS:000287248100018.
 95. Hoering A, **LeBlanc M**, Crowley J. Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents. *Clin Cancer Res.* 2011;17(4):640-6. doi: 10.1158/1078-0432.Ccr-10-1262. PubMed PMID: WOS:000287913200003.
 96. Rimsza LM, Unger JM, Tome ME, **LeBlanc ML**. A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma. *Plos One.* 2011;6(8). doi: ARTN e2226710.1371/journal.pone.0022267. PubMed PMID: WOS:000293561200010.
 97. Rubinstein L, **LeBlanc M**, Smith MA. More randomization in phase II trials: necessary but not sufficient. *J Natl Cancer Inst.* 2011;103(14):1075-7. Epub 20110627. doi: 10.1093/jnci/djr238. PubMed PMID: 21709273; PubMed Central PMCID: PMC3139589.
 98. Dai JY, Kooperberg C, **LeBlanc M**, Prentice RL. Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. *Biometrika.* 2012;99(4):929-44. Epub 20120925. doi: 10.1093/biomet/ass044. PubMed PMID: 23843674; PubMed Central PMCID: PMC3629859.
 99. **LeBlanc M**, Crowley J. Prognostic groups by tree-based partitioning and data refinement methods. In: Hoering A CJ, editor. *Handbook of statistics in clinical oncology.* 3rd ed: CRC Press; 2012. p.

505-28.

100. **LeBlanc M**, Tangen C. Choosing Phase II Endpoints and Designs: Evaluating the Possibilities. *Clin Cancer Res.* 2012;18(8):2130-2. doi: 10.1158/1078-0432.Ccr-12-0454. PubMed PMID: WOS:000302907300004.
101. **LeBlanc MR**, C; Crowley J. Phase II with Multiple Subgroups: Designs Incorporating Disease Subtype or Genetic Heterogeneity. In: Hoering A CJ, editor. *Handbook of Statistics in Clinical Oncology*. 3rd ed: Chapman and Hall/CRC; 2012. p. 163-74.
102. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, **LeBlanc M**, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. *P Natl Acad Sci USA.* 2012;109(20):7859-64. doi: 10.1073/pnas.1114718109. PubMed PMID: WOS:000304369800062.
103. Othus M, Barlogie B, **LeBlanc ML**, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. *Clin Cancer Res.* 2012;18(14):3731-6. Epub 20120606. doi: 10.1158/1078-0432.CCR-11-2859. PubMed PMID: 22675175; PubMed Central PMCID: PMC3744099.
104. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, **LeBlanc M**, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. *Haematol-Hematol J.* 2012;97(6):937-42. doi: 10.3324/haematol.2011.050419. PubMed PMID: 22550175.
105. Rudser KD, **LeBlanc ML**, Emerson SS. Distribution-free inference on contrasts of arbitrary summary measures of survival. *Statistics in Medicine.* 2012;31(16):1722-37. doi: 10.1002/sim.4505. PubMed PMID: WOS:000305616000006.
106. Schilsky RL, Doroshow JH, **LeBlanc M**, Conley BA. Development and Use of Integral Assays in Clinical Trials. *Clin Cancer Res.* 2012;18(6):1540-6. doi: 10.1158/1078-0432.Ccr-11-2202. PubMed PMID: WOS:000301672400010.
107. Stopeck AT, Unger JM, Rimsza LM, **LeBlanc M**, Farnsworth B, Iannone M, et al. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. *Blood.* 2012;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. PubMed PMID: WOS:000307449300011.
108. Bernstein SH, Epner E, Unger JM, **LeBlanc M**, Cebula E, Burack R, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. *Ann Oncol.* 2013;24(6):1587-93. doi: 10.1093/annonc/mdt070. PubMed PMID: WOS:000320741500025.
109. Dey J, Dubuc AM, Pedro KD, Thirstrup D, Mecham B, Northcott PA, **LeBlanc M**, et al. MyoD Is a Tumor Suppressor Gene in Medulloblastoma. *Cancer Research.* 2013;73(22):6828-37. doi: 10.1158/0008-5472.Can-13-0730-T. PubMed PMID: WOS:000327321700027.
110. Hoering A, Mitchell A, **LeBlanc M**, Crowley J. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents. *Clin Trials.* 2013;10(3):422-9. Epub 20130325. doi: 10.1177/1740774513480961. PubMed PMID: 23529697; PubMed Central PMCID: PMC3744092.
111. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, **LeBlanc M**, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. *Cancer.* 2013;119(2):371-9. Epub 20120725. doi: 10.1002/cncr.27733. PubMed PMID: 22833464; PubMed Central PMCID: PMC3485430.
112. Mehta S, Moon J, Hashmi M, **LeBlanc M**, Huang CH, Rinehart E, et al. Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: A study based on SWOG protocol S0420. *Oncol Rep.* 2013;29(6):2095-100. doi: 10.3892/or.2013.2374. PubMed PMID: WOS:000319232800001.
113. Pashova H, **LeBlanc M**, Kooperberg C. Boosting for detection of gene-environment interactions. *Stat Med.* 2013;32(2):255-66. Epub 20120705. doi: 10.1002/sim.5444. PubMed PMID: 22764060; PubMed Central PMCID: PMC3561470.
114. Press OW, Unger JM, Rimsza LM, Friedberg JW, **LeBlanc M**, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. *J Clin Oncol.* 2013;31(3):314-20. Epub 20121210. doi: 10.1200/JCO.2012.42.4101. PubMed PMID: 23233710; PubMed Central PMCID: PMC3732010.
115. Press OW, Unger JM, Rimsza LM, Friedberg JW, **LeBlanc M**, Czuczman MS, et al. A comparative

- analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. *Clin Cancer Res.* 2013;19(23):6624-32. Epub 20131015. doi: 10.1158/1078-0432.CCR-13-1120. PubMed PMID: 24130072; PubMed Central PMCID: PMC3872052.
116. Redman MW, Goldman BH, **LeBlanc M**, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. *Clin Cancer Res.* 2013;19(10):2646-56. doi: 10.1158/1078-0432.CCR-12-2939. PubMed PMID: 23669424; PubMed Central PMCID: PMC4131693.
 117. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, **LeBlanc M**, et al. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. *New England Journal of Medicine.* 2013;369(18):1681-90. doi: 10.1056/NEJMoal301077. PubMed PMID: WOS:000326311300006.
 118. Cook JR, Goldman B, Tubbs RR, Rimsza L, **LeBlanc M**, Stiff P, et al. Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas. *Am J Surg Pathol.* 2014;38(4):494-501. doi: 10.1097/Pas.0000000000000147. PubMed PMID: WOS:000333391300006.
 119. Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, **LeBlanc M**, et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. *Brit J Haematol.* 2014;166(3):382-9. doi: 10.1111/bjh.12906. PubMed PMID: WOS:000339478800010.
 120. Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, **LeBlanc ML**, et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. *Am J Hematol.* 2014;89(6):639-45. doi: 10.1002/ajh.23709. PubMed PMID: WOS:000336618600215.
 121. Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, **LeBlanc M**, et al. Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. *Clin Cancer Res.* 2014;20(16):4210-7. doi: 10.1158/1078-0432.Ccr-14-0521. PubMed PMID: WOS:000341186100006.
 122. Philip PA, Chansky K, **LeBlanc M**, Rubinstein L, Seymour L, Ivy SP, et al. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. *Clin Cancer Res.* 2014;20(16):4176-85. Epub 20140609. doi: 10.1158/1078-0432.CCR-13-2024. PubMed PMID: 24914040; PubMed Central PMCID: PMC4296727.
 123. Unger JM, Barlow WE, Martin DP, Ramsey SD, **LeBlanc M**, Etzioni R, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. *J Natl Cancer Inst.* 2014;106(3):dju002. Epub 20140313. doi: 10.1093/jnci/dju002. PubMed PMID: 24627276; PubMed Central PMCID: PMC3982777.
 124. Barr PM, Li HL, Spier C, Mahadevan D, **LeBlanc M**, Haq MU, et al. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. *J Clin Oncol.* 2015;33(21):2399-U105. doi: 10.1200/Jco.2014.60.6327. PubMed PMID: WOS:000361653900012.
 125. Dazard JE, Choe M, **LeBlanc M**, Rao JS. R package PRIMsrc: Bump Hunting by Patient Rule Induction Method for Survival, Regression and Classification. *Proc Am Stat Assoc.* 2015;2015:650-64. PubMed PMID: 26798326; PubMed Central PMCID: PMC4718587.
 126. Herbst RS, Gandara DR, Hirsch FR, Redman MW, **LeBlanc M**, Mack PC, et al. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. *Clin Cancer Res.* 2015;21(7):1514-24. Epub 20150213. doi: 10.1158/1078-0432.CCR-13-3473. PubMed PMID: 25680375; PubMed Central PMCID: PMC4654466.
 127. Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, **LeBlanc M**, et al. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. *J Clin Oncol.* 2015;33(13):1482-90. doi: 10.1200/Jco.2014.57.5092. PubMed PMID: WOS:000353230100011.
 128. Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, **LeBlanc M**, et al. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. *Blood.* 2015;125(6):992-8. Epub 20141124. doi: 10.1182/blood-2014-06-583369. PubMed PMID: 25422100; PubMed Central PMCID: PMC4319239.
 129. Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, **LeBlanc M**, et al. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell

- lymphoma: SWOG S0313. *Blood*. 2015;125(2):236-41. Epub 20141113. doi: 10.1182/blood-2014-06-584623. PubMed PMID: 25395425; PubMed Central PMCID: PMC4287635.
130. Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, **LeBlanc M**, et al. The diffusion of docetaxel in patients with metastatic prostate cancer. *J Natl Cancer Inst*. 2015;107(2). Epub 20141224. doi: 10.1093/jnci/dju412. PubMed PMID: 25540245; PubMed Central PMCID: PMC4326312.
131. **LeBlanc M**, Tangen C. Surrogates for Survival or Other End Points in Oncology. *JAMA Oncol*. 2016;2(2):263-4. doi: 10.1001/jamaoncol.2015.4711. PubMed PMID: 26605695.
132. Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, **LeBlanc M**, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. *J Clin Oncol*. 2016;34(17):2020-7. Epub 20160411. doi: 10.1200/JCO.2015.63.1119. PubMed PMID: 27069074; PubMed Central PMCID: PMC4966513.
133. Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, **LeBlanc M**, et al. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. *Leuk Lymphoma*. 2016;57(10):2359-69. Epub 20160112. doi: 10.3109/10428194.2015.1135431. PubMed PMID: 26758422; PubMed Central PMCID: PMC5140034.
134. Puvvada SD, Stiff PJ, **LeBlanc M**, Cook JR, Couban S, Leonard JP, et al. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. *Br J Haematol*. 2016;174(5):686-91. Epub 20160413. doi: 10.1111/bjh.14100. PubMed PMID: 27072903; PubMed Central PMCID: PMC5125530.
135. Stephens DM, Li H, **LeBlanc ML**, Puvvada SD, Persky D, Friedberg JW, et al. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. *J Clin Oncol*. 2016;34(25):2997-3004. Epub 20160705. doi: 10.1200/JCO.2015.65.4582. PubMed PMID: 27382104; PubMed Central PMCID: PMC5012710.
136. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, **LeBlanc M**, et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. *Br J Haematol*. 2016;172(2):208-18. Epub 20151022. doi: 10.1111/bjh.13818. PubMed PMID: 26492567; PubMed Central PMCID: PMC4710555.
137. Unger JM, Barlow WE, Ramsey SD, **LeBlanc M**, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. *JAMA Oncol*. 2016;2(7):875-81. doi: 10.1001/jamaoncol.2015.6487. PubMed PMID: 26967260; PubMed Central PMCID: PMC4945370.
138. Blanke C, **LeBlanc M**, Hershman D, Ellis L, Meyskens F. Characterizing 18 Years of the Death With Dignity Act in Oregon. *JAMA Oncol*. 2017;3(10):1403-6. doi: 10.1001/jamaoncol.2017.0243. PubMed PMID: 28384683; PubMed Central PMCID: PMC5824315.
139. Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, **LeBlanc M**, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. *Br J Haematol*. 2017;176(5):759-69. Epub 20161219. doi: 10.1111/bjh.14480. PubMed PMID: 27992063; PubMed Central PMCID: PMC5318240.
140. Greenlee H, Unger JM, **LeBlanc M**, Ramsey S, Hershman DL. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. *Cancer Epidemiol Biomarkers Prev*. 2017;26(1):21-9. Epub 20161216. doi: 10.1158/1055-9965.EPI-15-1336. PubMed PMID: 27986655; PubMed Central PMCID: PMC5370550.
141. Kerr KF, **LeBlanc M**, Janes H. Comparisons of cancer staging systems should be based on overall performance in the population. *Clin Trials*. 2017;14(6):659-60. Epub 20170818. doi: 10.1177/1740774517722141. PubMed PMID: 28819997; PubMed Central PMCID: PMC5714691.
142. **LeBlanc M**. A smooth basis for clinical subgroup analysis. In: Matsui S, Crowley J, editors. *Frontiers of biostatistical methods and applications in clinical oncology*. 1 ed. Singapore: Springer; 2017. p. 243-56.
143. Pashova H, **LeBlanc M**, Kooperberg C. Structured detection of interactions with the directed lasso. *Stat Biosci*. 2017;9(2):676-91. Epub 20161129. doi: 10.1007/s12561-016-9184-6. PubMed PMID: 29292402; PubMed Central PMCID: PMC5747322.
144. Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, **LeBlanc M**, et al. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. *J Natl Cancer Inst*. 2017;109(1). Epub 20161231. doi: 10.1093/jnci/djw263. PubMed PMID: 28040733; PubMed Central

PMCID: PMC6059122.

145. Unger JM, **LeBlanc M**, Blanke CD. The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. *JAMA Oncol.* 2017;3(10):1345-51. doi: 10.1001/jamaoncol.2017.0762. PubMed PMID: 28586789; PubMed Central PMCID: PMC5710507.
146. Unger JM, **LeBlanc ML**, Blanke CD. The impact of positive SWOG treatment trials on population survival. *J Clin Oncol.* 2017;35. doi: 10.1200/JCO.2017.35.15_suppl.6513. PubMed PMID: WOS:000411931706009.
147. Barr PM, Li H, Burack WR, **LeBlanc M**, Smith SM, Gopal AK, et al. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. *Lancet Haematol.* 2018;5(3):e102-e8. Epub 20180126. doi: 10.1016/S2352-3026(18)30001-2. PubMed PMID: 29396094; PubMed Central PMCID: PMC6501182.
148. Dai JY, Liang CJ, **LeBlanc M**, Prentice RL, Janes H. Case-only approach to identifying markers predicting treatment effects on the relative risk scale. *Biometrics.* 2018;74(2):753-63. Epub 20170928. doi: 10.1111/biom.12789. PubMed PMID: 28960244; PubMed Central PMCID: PMC5874156.
149. Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, **LeBlanc M**, et al. A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. *Am J Hematol.* 2018;93(4):486-93. Epub 20180125. doi: 10.1002/ajh.25010. PubMed PMID: 29266344; PubMed Central PMCID: PMC5842116.
150. Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, **LeBlanc M**, et al. Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. *Haematologica.* 2018;103(4):e151-e3. Epub 20180222. doi: 10.3324/haematol.2017.175059. PubMed PMID: 29472351; PubMed Central PMCID: PMC5865434.
151. Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, **LeBlanc M**, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. *J Clin Oncol.* 2018;36(7):697-703. Epub 20180122. doi: 10.1200/JCO.2017.74.5083. PubMed PMID: 29356608; PubMed Central PMCID: PMC6553811.
152. Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, **LeBlanc M**, et al. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). *Biol Blood Marrow Transplant.* 2018;24(4):700-7. Epub 20171228. doi: 10.1016/j.bbmt.2017.12.798. PubMed PMID: 29289757; PubMed Central PMCID: PMC5965270.
153. Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM, Jr., Klein EA, **LeBlanc M**, et al. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. *Cancer Epidemiol.* 2018;55:117-22. Epub 20180621. doi: 10.1016/j.canep.2018.06.005. PubMed PMID: 29936140; PubMed Central PMCID: PMC6625804.
154. Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, **LeBlanc M**, et al. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. *Leuk Lymphoma.* 2019;60(8):1934-41. Epub 20190110. doi: 10.1080/10428194.2018.1563691. PubMed PMID: 30628511; PubMed Central PMCID: PMC6620162.
155. Dai JY, **LeBlanc M**. Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints. *J R Stat Soc Ser C Appl Stat.* 2019;68(5):1371-91. Epub 20190708. doi: 10.1111/rssc.12366. PubMed PMID: 32489221; PubMed Central PMCID: PMC7266264.
156. Dai JY, **LeBlanc M**, Goodman PJ, Lucia MS, Thompson IM, Tangen CM. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. *Cancer Prev Res (Phila).* 2019;12(2):113-20. Epub 20181211. doi: 10.1158/1940-6207.CAPR-18-0284. PubMed PMID: 30538099; PubMed Central PMCID: PMC6365187.
157. Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, **LeBlanc M**, et al. Long-Term Effects of Finasteride on Prostate Cancer Mortality. *N Engl J Med.* 2019;380(4):393-4. doi: 10.1056/NEJMc1809961. PubMed PMID: 30673548.
158. Hsi ED, Li H, Nixon AB, Schoder H, Bartlett NL, **LeBlanc M**, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. *Blood.*

- 2019;133(16):1762-5. Epub 20190205. doi: 10.1182/blood-2018-08-870915. PubMed PMID: 30723079; PubMed Central PMCID: PMC6473498.
159. Kamdar M, Li H, Chen RW, Rimsza LM, **LeBlanc ML**, Fenske TS, et al. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. *Blood Adv.* 2019;3(20):3132-5. doi: 10.1182/bloodadvances.2019000526. PubMed PMID: 31648328; PubMed Central PMCID: PMC6849956.
160. Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, **LeBlanc M**, et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. *Blood.* 2019;133(1):81-93. Epub 20181116. doi: 10.1182/blood-2018-07-865428. PubMed PMID: 30446494; PubMed Central PMCID: PMC6318431.
161. Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, **LeBlanc M**, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. *Blood.* 2019;134(15):1238-46. doi: 10.1182/blood.2019000719. PubMed PMID: 31331918; PubMed Central PMCID: PMC6788007.
162. Unger JM, Nghiem VT, Hershman DL, Vaidya R, **LeBlanc M**, Blanke CD. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. *JAMA Netw Open.* 2019;2(9):e1910593. Epub 20190904. doi: 10.1001/jamanetworkopen.2019.10593. PubMed PMID: 31483471; PubMed Central PMCID: PMC6727679.
163. Zhao YQ, Redman MW, **LeBlanc ML**. Quantifying treatment effects using the personalized chance of longer survival. *Stat Med.* 2019;38(28):5317-31. Epub 20190909. doi: 10.1002/sim.8363. PubMed PMID: 31502297; PubMed Central PMCID: PMC6842038.
164. Zhao YQ, Zeng D, Tangen CM, **LeBlanc ML**. Robustifying Trial-Derived Optimal Treatment Rules for A Target Population. *Electron J Stat.* 2019;13(1):1717-43. Epub 20190430. doi: 10.1214/19-EJS1540. PubMed PMID: 31440323; PubMed Central PMCID: PMC6705616.
165. Ha CS, **LeBlanc M**, Schoder H, Pinnix CC, Bartlett NL, Evens AM, et al. Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. *Leuk Lymphoma.* 2020;61(10):2442-7. Epub 20200526. doi: 10.1080/10428194.2020.1768388. PubMed PMID: 32452714; PubMed Central PMCID: PMC7704391.
166. Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, **LeBlanc M**, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. *J Clin Oncol.* 2020;38(26):3003-11. Epub 20200713. doi: 10.1200/JCO.20.00999. PubMed PMID: 32658627; PubMed Central PMCID: PMC7479758.
167. Persky DO, Smith SM, **LeBlanc ML**, Friedberg JW. Reply to E. Hawkes et al. *J Clin Oncol.* 2020;38(35):4222-3. Epub 20201026. doi: 10.1200/JCO.20.02856. PubMed PMID: 33104437.
168. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. *Lancet Oncol.* 2020;21(12):1589-601. Epub 20201027. doi: 10.1016/S1470-2045(20)30475-7. PubMed PMID: 33125909; PubMed Central PMCID: PMC8109255.
169. Unger JM, Blanke CD, **LeBlanc M**, Barlow WE, Vaidya R, Ramsey SD, et al. Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. *JAMA Netw Open.* 2020;3(4):e203842. Epub 20200401. doi: 10.1001/jamanetworkopen.2020.3842. PubMed PMID: 32352530; PubMed Central PMCID: PMC7193331.
170. Unger JM, Blanke CD, **LeBlanc M**, Hershman DL. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. *JAMA Netw Open.* 2020;3(6):e2010651. Epub 20200601. doi: 10.1001/jamanetworkopen.2020.10651. PubMed PMID: 32478845; PubMed Central PMCID: PMC7265094.
171. Zhao YQ, **LeBlanc ML**. Designing precision medicine trials to yield a greater population impact. *Biometrics.* 2020;76(2):643-53. Epub 20191107. doi: 10.1111/biom.13161. PubMed PMID: 31598964; PubMed Central PMCID: PMC7211185.
172. Moon J, **LeBlanc M**, Othus M. Accounting for All Patients in Waterfall Plots. *JCO Clin Cancer Inform.* 2021;5:414-20. doi: 10.1200/CCI.20.00150. PubMed PMID: 33830787; PubMed Central PMCID: PMC8240789.
173. Unger JM, Xiao H, **LeBlanc M**, Hershman DL, Blanke CD. Cancer Clinical Trial Participation at the

- 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. *JAMA Netw Open*. 2021;4(7):e2118433. Epub 20210701. doi: 10.1001/jamanetworkopen.2021.18433. PubMed PMID: 34323986; PubMed Central PMCID: PMC8323000.
174. Brem EA, Li H, Beaven AW, Caimi PF, Cerchiatti L, Alizadeh AA, **LeBlanc M**, et al. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. *J Geriatr Oncol*. 2022;13(2):258-64. Epub 20211020. doi: 10.1016/j.jgo.2021.10.003. PubMed PMID: 34686472; PubMed Central PMCID: PMC9879719.
 175. Dai JY, Stanford JL, **LeBlanc M**. A multiple-testing procedure for high-dimensional mediation hypotheses. *J Am Stat Assoc*. 2022;117(537):198-213. Epub 20200624. doi: 10.1080/01621459.2020.1765785. PubMed PMID: 35400115; PubMed Central PMCID: PMC8991388.
 178. Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, **LeBlanc M**, et al. Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. *Haematologica*. 2022;107(11):2732-6. Epub 20221101. doi: 10.3324/haematol.2022.281004. PubMed PMID: 35833300; PubMed Central PMCID: PMC9614528.
 179. Unger JM, Vaidya R, Albain KS, **LeBlanc M**, Minasian LM, Gotay CC, et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. *J Clin Oncol*. 2022;40(13):1474-86. Epub 20220204. doi: 10.1200/JCO.21.02377. PubMed PMID: 35119908; PubMed Central PMCID: PMC9061143.
 180. Zhang S, **LeBlanc ML**, Zhao YQ. Restricted survival benefit with right-censored data. *Biom J*. 2022;64(4):696-713. Epub 20211230. doi: 10.1002/bimj.202000392. PubMed PMID: 34970772; PubMed Central PMCID: PMC9162957.
 181. Burack WR, Li H, Adlowitz D, Spence JM, Rimsza LM, Shadman M, **LeBlanc M**, et al. Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma. *Blood Adv*. 2023;7(17):5082-90. doi: 10.1182/bloodadvances.2022009467. PubMed PMID: 37379264; PubMed Central PMCID: PMC10471938.
 182. Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, **LeBlanc ML**, et al. The New NCI Precision Medicine Trials. *Clin Cancer Res*. 2023;29(23):4728-32. doi: 10.1158/1078-0432.CCR-23-0917. PubMed PMID: 37531248; PubMed Central PMCID: PMC10690084.
 183. Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, **LeBlanc M**, et al. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. *J Clin Oncol*. 2023;41(2):336-42. Epub 20220705. doi: 10.1200/JCO.21.02301. PubMed PMID: 35787017; PubMed Central PMCID: PMC9839232.
 184. Unger JM, **LeBlanc M**, George S, Wolmark N, Curran WJ, Jr., O'Dwyer PJ, et al. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. *J Clin Oncol*. 2023;41(11):2020-8. Epub 20221208. doi: 10.1200/JCO.22.01826. PubMed PMID: 36480773; PubMed Central PMCID: PMC10082246.
 185. Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, **LeBlanc M**, et al. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. *J Natl Cancer Inst*. 2023;115(4):437-46. doi: 10.1093/jnci/djad003. PubMed PMID: 36625510; PubMed Central PMCID: PMC10086628.
 186. Unger JM, Till C, Hwang JP, Arnold KB, **LeBlanc M**, Hershman DL, et al. Risk prediction of hepatitis B or C or HIV among newly diagnosed cancer patients. *J Natl Cancer Inst*. 2023;115(6):703-11. doi: 10.1093/jnci/djad053. PubMed PMID: 36946291; PubMed Central PMCID: PMC10248838.
 187. Unger JM, Xiao H, Vaidya R, **LeBlanc M**, Hershman DL. Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials. *JAMA Oncol*. 2023;9(10):1371-9. doi: 10.1001/jamaoncol.2023.2800. PubMed PMID: 37590003; PubMed Central PMCID: PMC10436183.
 188. Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, **LeBlanc M**, et al. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). *JCO Precis Oncol*. 2023;7:e2300218. doi: 10.1200/PO.23.00218. PubMed PMID: 37677122; PubMed Central PMCID: PMC10581630.
 189. Herrera AF, **LeBlanc M**, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. *N Engl J Med*. 2024;391(15):1379-89. doi:

- 10.1056/NEJMoa2405888. PubMed PMID: 39413375; PubMed Central PMCID: PMC11488644.
190. Janczewski LM, Browner A, Cotler J, Nelson H, Ballman KV, **LeBlanc M**, et al. Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. *Cancer*. 2024;130(9):1702-10. Epub 20231222. doi: 10.1002/cncr.35155. PubMed PMID: 38140735.
191. Lara PN, Jr., Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, **LeBlanc M**, et al. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. *Eur Urol*. 2024;85(2):171-6. Epub 20230419. doi: 10.1016/j.eururo.2023.03.036. PubMed PMID: 37085425; PubMed Central PMCID: PMC10662935.
192. **LeBlanc ML**. Using Cure Models for Trial Analysis and Design. *J Clin Oncol*. 2024;JCO2401918. Epub 20241125. doi: 10.1200/JCO-24-01918. PubMed PMID: 39586040.
193. Unger JM, Xiao H, Vaidya R, **LeBlanc M**. Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials. *J Clin Oncol*. 2024;42(33):3917-25. Epub 20240927. doi: 10.1200/JCO.24.00843. PubMed PMID: 39331494; PubMed Central PMCID: PMC11575909.
194. Herrera AF, **LeBlanc M**, Friedberg JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply. *N Engl J Med*. 2025;392(1):102. doi: 10.1056/NEJMc2414269. PubMed PMID: 39752312.
195. Unger JM, Till C, Tangen CM, Hershman DL, Goodman PJ, **LeBlanc M**, et al. Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. *JAMA Oncol*. 2024. Epub 20241107. doi: 10.1001/jamaoncol.2024.4397. PubMed PMID: 39509091; PubMed Central PMCID: PMC11544550.
196. Samorodnitsky S, Othus M, **LeBlanc M**, Wu MC. Reverse Selection Designs for Accommodating Multiple Control Arms. *Clin Cancer Res*. 2024. Epub 20241018. doi: 10.1158/1078-0432.CCR-24-1282. PubMed PMID: 39422601.

B. Book Chapters

1. **LeBlanc M**. Tree-based tools for censored survival data, Proceedings of the XV International Biometrics Conference, pp. 123-138, 1990.
2. **LeBlanc M**. A stratification option for tree-based regression. Proceedings of the 23rd symposium on the interface between computing science and statistics. pp. 403-406, 1991.
3. Feld R, Sagman U, **LeBlanc M**. Staging, classification and prognostic factors for small cell lung cancer in lung cancer. Principles and Practice, Lippincott-Raven, 1995.
4. **LeBlanc M**, Crowley J. A review of tree-based prognostic models. Recent Advances in Clinical Trial Design and Analysis. Peter F. Thall (ed.), Kluwer Academic Publishers pp. 113-124, 1995.
5. Crowley J, **LeBlanc M**, Gentleman R, Salmon S. Exploratory methods in survival analysis. Hira Koul (ed). Analysis of Censored Data, IMS Lecture Notes-monograph Series pp. 55-78, 1996.
6. Miller T, Dahlberg S, Cassady J, Budd G, Spier C, Grogan T, Carlin S, Chase E, **LeBlanc M**, Fisher R. CHOP plus radiotherapy is superior to CHOP alone for adjuvant therapy of resected localized unfavorable non-Hodgkin's lymphoma: A Southwest Oncology Group study. Adjuvant Therapy of Cancer VIII, Lippincott-Raven, 1996.
7. Crowley J, **LeBlanc M**, Jacobson J, Salmon S. Some exploratory methods for survival data. In proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. DY Lin and T.R. Fleming, Eds. Springer-Verlag, New York pp. 199-230, 1997.
8. **LeBlanc M**. Tree-based methods for prognostic stratification. In: Handbook of Statistics in Clinical Oncology: Crowley, J.(ed) Marcel-Dekker; pp 457-472, 2001.
9. **LeBlanc M**. Regression Trees. In: Encyclopedia of Environmetrics, Abdel El-Shaarawi (ed), Walter Piegorsch (ed), Wiley. 1734-1738, 2002.
10. **LeBlanc M**. Tree structured methods. In: Encyclopedia of Environmetrics, Abdel El-Shaarawi (ed), Walter Piegorsch (ed), Wiley, 2242-2243, 2002.
11. Ruczinski I, Kooperberg C, **LeBlanc M**. Logic regression methods and software. In proceedings of the MRSI workshop, Workshop on nonlinear estimation and classification, Springer, 333-344, 2002.
12. Pauler DK, Hardin J, Faulkner J, **LeBlanc M**, Crowley JJ. Survival analysis with gene expression arrays. In: Handbook of Statistics, CR Rao (ed), N Balakrishnan (ed), Amsterdam:Elsevier Science, 675-687, 2004.
13. **LeBlanc M**, Rasmussen E, Crowley J: Constructing Prognostic Groups by Tree-based Partitioning and Peeling Methods. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in

- Clinical Oncology (ed 2). New York, Marcel Dekker, Inc, 2006
14. Anderson G, **LeBlanc** M, Liu PY, Crowley J: On Use of Covariates in Randomization and Analysis of Clinical Trials. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). New York, Marcel Dekker, Inc., 2006
 15. Liu PY, Moon J, **LeBlanc** M: Phase II Selection Designs. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). New York, Marcel Dekker, Inc., 2006
 16. Kooperberg C, **LeBlanc** M: Multivariate Nonparametric Regression. In: Ronghui X, Xiachun L (eds): High-Dimensional Data Analysis in Cancer Research. Springer, 35-58, 2009.
 17. Liu PY, Moon J, **LeBlanc** M: Phase II Selection Designs. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). Boca Raton, Chapman and Hall/CRC, 155-166, 2006.
 18. Kooperberg C, **LeBlanc** M: Multivariate Nonparametric Regression. In: Ronghui X, Xiachun L (eds): High-Dimensional Data Analysis in Cancer Research. Springer, 35-58, 2009.
 19. Liu PY, Moon J, **LeBlanc** M. Randomized Phase II Selection Designs, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Hoering and John Crowley, Chapman and Hall/CRC, 151-162, 2012.
 20. Anderson G, **LeBlanc** M, Liu PY, Crowley J. On Use of Covariates in Randomization and Analysis of Clinical Trials, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Hoering and John Crowley Chapman and Hall/CRC, 185-198, 2012
 21. Hoering A, **LeBlanc** M, Crowley J. Phase III trials for Targeted Agents, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Hoering and John Crowley, Chapman and Hall/CRC, 251-264, 2012
 22. **LeBlanc** M, Crowley J. Prognostic Groups by Tree-based Partitioning and Data Refinement Methods, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Crowley and John Hoering Chapman and Hall/CRC, 505-528, 2012
 23. **LeBlanc** M, Rankin C, Crowley J. Phase II with Multiple Subgroups: designs incorporating disease subtype or genetic heterogeneity, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Crowley and John Hoering Chapman and Hall/CRC, 163-174, 2012
 24. **LeBlanc** M, Goldman B, Kooperberg, C. Methods for SNP Regression Analysis in Clinical Studies: Selection, Shrinkage and Logic, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Crowley and John Hoering Chapman and Hall/CRC, 591-564, 2012
 25. **LeBlanc** M. Regression Trees. In: Encyclopedia of Environmetrics, Brian Everett, Wiley StatsRef-Statistics Reference Online. (ed), Wiley. To Appear 2015.
 26. Hoering A, **LeBlanc** M, Crowley J. Phase III Randomized Clinical Trials Using Biomarkers: Comparison of Randomized Clinical Trial Designs for Targeted Agents, in Design and Analysis of Clinical Trials for Predictive Medicine, Chapman and Hall/CRC, 147-164, 2015.
 27. Hoering A, **LeBlanc** M, Crowley J. Comparison of Randomized Clinical Trial Designs for Targeted Agents, in Design and Analysis of Clinical Trials for Predictive Medicine, Taylor and Francis Group LLC, Boca Raton, FL 33487, 2015.
 28. **LeBlanc**, A Smooth Basis for Clinical Subgroup Analysis, in Frontiers of Biostatistical Methods and Applications in Clinical Oncology Editors: Matsui, Shigeyuki, Crowley, John (Eds.) pp 243-256, 2017.
 29. Tangen C, **LeBlanc** M. Efficient Management of a Publicly Funded Cancer Clinical Trials Portfolio, Steven Piantadosi and Curtis L. Meinert (Eds): Principles and Practice of Clinical Trials, 2020, <https://doi.org/10.1007/978-3-319-52677-5>

8. PATENTS AND OTHER INTELLECTUAL PROPERTY

N/A

9. FUNDING HISTORY

A. 1) NIH Current

2019-2025 Sponsor: U10 CA180819 (LeBlanc)
 Title: SWOG Statistics and Data Management Center (SDMC)
 Total Award Costs: \$48,135,258

Role: PI/Director

- 2019-2025 Sponsor: UG1CA189974 (Tangen, Blanke, Hershman)
 Title: SWOG NCORP Research Base
 Total Award Costs: \$3,376,835
 Role: Co-Investigator
- 2019-2024 Sponsor: NIH 2 UO1CA182883 (Tangen)
 Title: PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research
 Total Award Costs: \$5,665,537
 Role: Co-Investigator
- 2018-2023 Sponsor: R01CA222833 (Dai)
 Title: Statistical Genetics and Genomics for Epidemiologic Research
 Total Award Costs: \$1,296,808
 Role: Co-Investigator
- 2020-2026 Sponsor NIH RFA-CA-20-002 (Ramirez)
 Title: SWOG Biospecimen Bank to Support NCI NCTN (U24)
 Total Award Costs: \$645,468
 Role: Consortium PI

Non-NIH

- 2014-Current SWOG-CTP
 Title SWOG SDMC Multiple Studies (currently 10 SWOG Clinical Trials)
 Role: PI

B. Pending Research Support (Under Review)

Multiple

C. Past

- 2008-2012 Sponsor: R01 CA90998 (LeBlanc)
 Title: Statistical Methods for Clinical Studies
 Role: PI
- 2010-2015 Sponsor: U10 CA38926 (LeBlanc)
 Title: Southwest Oncology Group Statistical
 Center
 Role: PI
- 2011-2015 Sponsor: R01 HG006124 (Kooperberg)
 Title: Adaptive Statistical Methods for Genetic Association
 Studies
 Role: Co-PI
- 2011-2016 Sponsor: R01 CA155360 (Olson)
 Title: Infant and Toddler Brain
 Tumors
 Role: Co-Investigator
- 2011-2017 Sponsor: P01 CA53996 (Prentice/Hsu)
 Title: Statistical Methods for Medical
 Studies
 Role: Co-Investigator

- 2012-2018 Sponsor: R01 HL114901 (Dai)
Title: Statistical Inference In Genome-Wide Association And Sequencing Studies
Role: Co-Investigator
- 2013-2016 Sponsor: OHSU 1004230 (LeBlanc)
Title: A Sero-Epidemiologic Survey and Cost-effectiveness Study of Screening for HIV, Hepatitis B and Hepatitis C Among Newly Diagnosed Cancer Patients Among SWOG-Affiliated Oncology Clinics
Role: Co-Investigator
- 2013-2018 Sponsor; UM1 CA182883 (Tangen)
Title: PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research
Role: Co-Investigator
- 2015-2018 Sponsor; R21CA198072 (Burack)
Title: Passenger Mutations Due to Activation-Induced Deaminase as Biomarkers in Lymphoma
Role: Co-Investigator

10. PUBLIC HEALTH PRACTICE ACTIVITIES

N/A

11. CONFERENCES AND SYMPOSIUMS

- 1990 International Biometric Conference Invited: Lecture on exploratory survival analysis. Budapest, July 2-6, 1990. *Tree-based tools for survival data*.
- 1992 Annual Meeting of the American Statistical Association, Boston, MA., August 9-11, 1992. Invited: *Discussion of two papers on new methods for neural networks* by Geoff Hinton and David Mackay.
- 1994 Annual Meeting of the Canadian Statistical Association, Banff, Alberta, May 8-11, 1994. Invited: *Adaptive Survival Models*.
- 1994 International Biometric Conference, Hamilton, Ontario, Canada, August 8-12, 1994. Invited: *Discussion of two papers on generalized additive models*.
- 1994 Annual Meeting of the American Statistical Association, Toronto, Ontario, Canada, August 14-18, 1994. Invited: *Tutorial on Tree-Based Methods for Survival Analysis*.
- 1995 Annual Meeting of the Biometric Society/WNAR, June 26-28, 1995. Invited: *Lecture on Shrinkage Trees*.
- 1995 Annual Meeting of the American Statistical Association, Orlando, Florida, August 13-17, 1995. Invited: *Lecture on Adaptive Regression Splines in the Cox model*.
- 1996 Annual Meeting of the Canadian Statistical Society, Waterloo, Ont, June 3-5, 1996. Invited: *Some Exploratory Methods for Survival Data*.
- 1996 Annual Meeting of the Biometric Society/WNAR, June 24-26, 1996. Invited: *Pruning and Shrinking Trees*.
- 1996 Annual Meeting of the American Statistical Association, Chicago, Illinois, August 5-7, 1996. Invited: *Tutorial on Survival Trees*.
- 1996 Statistical Modeling of Discrete Data and Structures, Munich, October 24-26, 1996. Invited: *Pruning and Shrinking Trees*.
- 1998 Annual Meeting of the Biometric Society/ENAR, Pittsburgh, PA, March 29-April 1, 1998. Invited: *Discussion of Exploratory Analysis Using Classification Trees*.

- 1998 The World of Genomics-Medical Applications and Social Implications, Santander, Spain, August 3-7, 1998. Invited: *Molecular Clinical and Epidemiological Studies: Design and Data Analysis* and *New Biostatistical Methods for Marker Analysis*.
- 2002 Current Advances and Trends in Nonparametric Statistics, Crete, Greece, July 15-19, 2002. Invited: *Partitioning, Peeling, and Logic for Prognostic Groups*.
- 2003 Annual Meeting of the Biometric Society/WNAR, Golden, Colorado, June 23-25, 2003. Invited: *Directed Indices for Exploring Gene Expression*.
- 2003 US-Japan Biostatistics Workshop, Kobe, Japan, September 26, 2003. Invited: *Gene Exploration and Correlation: Applications to Lymphoma*.
- 2004 Fifth Biennial International Conference on Statistics, Probability and Related Areas, Athens, Georgia, May 14-16, 2004. Invited: *Extreme Models*.
- 2004 Second US-Japan Biostatistics Workshop, Seattle, WA, September 23-24, 2004. Invited: *Extreme Regression and Other New Methods for Prognostic Analysis*.
- 2005 Annual Meeting of the American Statistical Association, Minneapolis, MN, August 7-11, 2005. Invited: *Extreme Regression Models for Prognosis*.
- 2005 US-Japan Biostatistics Workshop, Kyoto, Japan, October 7, 2005. Invited: *Prognostic Modeling Rules*.
- 2006 Cooperative Group Statisticians Meeting, Seattle, WA, August 6, 2006: *Interim Analyses with Early Endpoints*.
- 2006 Enhancing Development of Genome-wide Association Methods (ENDGAME) Meeting, Herndon, VA, December 1, 2006. *Subgroup Weighted Association Tests*.
- 2007 Annual Meeting of the American Statistical Association, Salt Lake City, UT, July 29 – August 2, 2007. *Subgroup Weighted Association Tests*.
- 2007 American Society of Clinical Oncology (ASCO), Phase II Development of Novel Therapeutics in Lymphoma, Aspen, CO, September 18-19, 2007. Invited: *Traditional Randomized and Screening Phase II Designs*.
- 2007 Annual INFORMS Meeting, Seattle, WA, November 4 – 7, 2007. Invited: *New Developments in Tree-based Methods with Applications to Targeted Medicine*.
- 2008 Recent Advances in Biological Process Workshop, Fred Hutchinson Cancer Research Center, Seattle WA, December 1-2, 2008. Invited: *Using Interactions to Find Main Effects in Genome-wide Association Studies*.
- 2009 The International Kurume Symposium on Biostatistics, Fukuoka, Japan, January 30-31, 2009. Invited: *New Strategies for Constructing Prognostic and Varying Treatment Efficacy Models for Survival Data: Applications to Cancer Clinical Trials*.
- 2009 Biostatistics Workshop in Cancer Research, Toronto, Canada, July 24-26, 2009. Invited: *Targeted Subgroup Effect Modeling*.
- 2010 Interface 2010: *Computational Statistics and Human Behavior*, Seattle, Washington, June 16-18, 2010. Invited: *Emerging Data from Clinical Trials*.
- 2010 ICSA 2010 Applied Statistics Symposium, Indianapolis, Indiana, June 20-23, 2010. Invited: *Using Models to Assess and Harness Interactions in High Dimensional Genomic Data*.
- 2011 Investigational Drug Steering Committee (IDSC) Meeting, March 15, 2011. Rockville, MD. Invited: *Historical Controls Database : Pancreatic Cancer and Advanced NSCLC*.
- 2011 Annual Biostatistics Research Day, Toronto CA. April 29, 2011. Invited: *Assessing Interactions and Associations in Modern Clinical Trials*.
- 2011 Society of Clinical Trials Meeting, Vancouver CA. May 16-19, 2011. Invited: *Soft Enrichment: Using Phase II Data for Designing Targeted Groups*.

- 2011 NCI Workshop on Criteria for Use of 'Omics-Based Predictors in Clinical Trials. June 23-24, 2011, Bethesda, MD. Invited: *Blinded Clinical Validations – Role of Honest Broker*.
- 2011 Annual Meeting of the American Statistical Association, Miami Beach, FL, Aug 1-4, 2011. Invited: *Using Interactions in Moderately Sized Randomized Studies*.
- 2012 Annual Meeting of the Biometric Society/ENAR, Washington DC, March 31-April 3, 2012. Invited: *Validating Clinical Performance of Predictors*.
- 2014 International Biometric Conference, Florence, IT, July 7-11, 2014. Invited: *Flexible subgroup treatment interaction modeling*
- 2014 Annual Meeting of the American Statistical Association, Boston MA, Aug 2-7, 2014. Invited: *A Smooth Basis for Prognostic Rules*
- 2014 Statistical Issues in Biomarker and drug development, Fields Institute, Toronto, November 9-11, 2014, Invited: *Some experience with biomarker driven cancer clinical trials*
- 2015 SWOG Plenary I, San Francisco CA, April 30, 2015, Invited: *Statistics for TM studies and bucket trials*.
- 2015 Annual Meeting of The Canadian Statistical Society, Halifax NS, June 15-17, 2015, Invited: *Refinement Rules for Prognosis and Enhanced Treatment Effect Subgroups*
- 2015 Annual Meeting of the American Statistical Association, Seattle WA, Aug 8-13, 2015, Some experience with biomarker driven cancer clinical trials
- 2016 Society of Clinical Trials Meeting, Montreal, CA, May 15-18, 2016. Invited: *Statistical Models in immuno-oncology*
- 2017 Annual Meeting of the Biometric Society/WNAR, Santa-Fe, New Mexico, June 25-28, 2017. Invited: *New Developments in Regression Trees*.
- 2017 Annual Meeting of the International Society of Clinical Biostatistics, Vigo Spain, July 10-13, 2017; *Subgroup modeling by case-only tree-based Regression*.
- 2018 Meeting of National Clinical Trial Network (NCTN) Biostatisticians (organizer and speaker), SWOG Statistics and Data Management Center within the NCTN, May 18, 2018.
- 2019 3rd Pacific Rim Cancer Biostatistics Conference, Portland OR, May 27-28, 2019, Invited: *Subgroup directed models of treatment efficacy*
- Annual Meeting of the American Statistical Association, Denver CO, July 27-Aug 1, 2019. Invited: *Designing precision medicine trials in oncology to yield greater population impact*
- Annual Conference of the International Society for Clinical Biostatistics, July 14-18, 2019. *Extreme Subgroup Directed Models of Treatment Efficacy*
- Annual Meeting of the American Statistical Association, Denver CO, July
- Ontario Biostatistics Training Initiative Workshop, Oct 29, 2019.
- Distinguished Lecture: *Clinical trial design strategies for precision medicine and master protocols in oncology*
- 2020 CREST International Symposium on Big Data Applications, Tokyo, Japan, January 13-14th. Invited: *Omics Directed Subgroup Models of Treatment Efficacy in Cancer Clinical Trials*
- Data-Driven Precision Medicine and Translational Research in the Era of Big Data, St Jude, Memphis TN. May 1(online) Invited: *Experiences in building sequential and platform precision medicine trials*
- SWOG Fall Group Meeting Plenary I, September 23-26 *SWOG Accrual during the Covid-19 Pandemic*
- 2021 SWOG Spring, Group Meeting, April 19-23, *Scientific Role of the CRA*. Virtual. Biostat Seminar, Experience with Building Sequential and Platform Precision Medicine Trials, May 3, Virtual.

- 2022 SWOG Spring Meeting, April 6-9, *Scientific Role of the CRA*.
Seattle, WA.
International Society for Clinical Biostatistics, August 21-24, *Using the Probability of Longer Survival to Assess the Efficacy of New Cancer Therapies*, New Castle, UK,
Statistics and Biopharmacy group of the SFdS (French Society of Statistics), September 19-21, *Subgroup rule induction for patient outcomes: examples and experience with machine learning methods for clinical data*, Paris France.
- 2023 SWOG Spring Meeting, San Francisco CA May 10-13, *Scientific Role of the CRA and Oishi Symposium Data for Interim Monitoring and Reporting of Clinical Trials*
Western North American Region of The International Biometric Society Anchorage Alaska, Invited: June 18-21, *Graphing the Probability of Longer Survival to Assess the Efficacy of New Cancer Therapies*
International Society of Clinical Biostatistics, Milan IT, August 27-31, *Utilizing Co-Primary Endpoints To Test For Clinically Significant Differences In Progression-free Survival*.
- 2024 Society of Clinical Trials, Invited Webinar, January 24, 2024 Cancer Clinical Trials in the 21st Century

12. UNIVERSITY SERVICE

University and Fred Hutchinson Cancer Research Center Committees

- 1992 MRC self-managed discussion group for young investigators, University of Toronto
- 1992-1993 Departmental committee for input to the Leyerle Commission, Department of Preventive Medicine and Biostatistics University of Toronto
- 1992-1994 Member of computer committee, Department of Statistics, University of Toronto
- 1993 Member of the statistical consulting committee, Department of Statistics
- 1993 Member of the strategic planning committee, Department of Preventive Medicine and Biostatistics, University of Toronto
- 1997-2000 Member of the curriculum committee, Department of Biostatistics, University of Washington
- 1998-2003 Member of statistical theory exam committee, Department of Biostatistics, University of Washington
- 1998-2006 Member of admissions committee, Department of Biostatistics, University of Washington
- 2001-2003 Member of faculty Senate, University of Washington
- 2000-present Member of faculty search and promotion committees, Fred Hutchinson Cancer Research Center

13. PROFESSIONALLY-RELATED COMMUNITY SERVICE

N/A

14. [OTHER PERTINENT INFORMATION AS NEEDED]

N/A

15. TEACHING HISTORY

University of Washington

- 1983-1984 Teaching Assistant, University of Waterloo
- 1987-1988 Teaching Assistant, University of Washington
- 1990-1994 Applied statistical training of biostatistics students through Research Services Unit (approximately 25 projects per year)

1990-1995	Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Rob Tibshirani), CHL4507
1991	Survival Analysis (currently CHL 3118) (with John McLaughlin), 1991.
1991	Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Rob Tibshirani), CHL4507
1992	Survival Analysis, CHL 4515
1992	Prospective Studies and Survival Analysis, CHL3118 (with John McLaughlin)
1993	Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Rob Tibshirani), CHL4507
1993	Survival Analysis, CHL 4515
1994	Prospective Studies and Survival Analysis, CHL3118 (with John McLaughlin)
1994	Survival Analysis, CHL 4515,
1997	Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Mike Escobar), CHL4507
1996	Biostat 580, Organized Seminars in Biostatistics
1997	Biostat 578, Special Topics: Non-parametric Estimation using Smoothers, Trees and Splines (with Charles Kooperberg)
2002-present	SWOG, Young Investigators Course

16. ADVISING AND FORMAL MENTORING

1990-current	Wendy Lou (M.Sc. Biostatistics) (with Paul Cory), Mohamed Abdoell (M.Sc. Biostatistics), Shi-Yun Shen (Ph.D. Biostatistics) (with Rob Tibshirani), Elizabeth Kexel (M.S. Biostatistics), Ingo Ruczinski (Ph.D. Statistics) (with Charles Kooperberg), Martha Nason (Ph.D. Biostatistics) (with Scott Emerson). James Dai (Ph.D. Biostatistics) (with Charles Kooperberg) Kyle Rudser (Ph.D. Biostatistics) (with Scott Emerson). Hristina Pashova (Ph.D. Biostatistics) (with Charles Kooperberg) Reed Sorrenson, (Ph.D, Health Metrics Sciences)
--------------	---